After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Both the seasonal flu vaccine and the updated COVID-19 vaccine are recommended annually for nearly everyone ages 6 months and older to prevent severe respiratory illness, hospitalizations, and death.

Houman Hemmati is under consideration to lead the FDA’s Center for Biologics Evaluation and Research. A final decision has ...

Add Yahoo as a preferred source to see more of our stories on Google. More than a week after a federal judge blocked Health and Human Services Secretary Robert F. Kennedy Jr.’s overhaul of both the ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to ...

The FDA will hold a public hearing June 12 to gather feedback on its Commissioner’s National Priority Voucher pilot program. The hearing will be held at the agency’s White Oak campus in Silver Spring, ...

"We found that they knew there were safety signals on myocarditis very early on in like January, February of 2021... they hid it, they downplayed it." Senator Ron Johnson (R-WI) tells John Solomon ...

FIVE ON YOUR HEALTH TONIGHT, A NEW TREATMENT OPTION FOR ADULTS LIVING WITH TYPE TWO DIABETES. THE FDA JUST APPROVED THE FIRST WEEKLY SHOT OF INSULIN TO CONTROL BLOOD SUGAR LEVELS. THE MEDICATION, A ...

Add Yahoo as a preferred source to see more of our stories on Google. It's an anniversary no one wants to celebrate, but an anniversary nonetheless. Thursday, March 19, marked six years since the ...

The one demographic that’s especially susceptible to COVID-19 hospitalizations but is ineligible for the vaccine? Infants under 6 months old. Their mothers, however, could be the missing link: New ...

March 2 (Reuters) - Intellia Therapeutics said on Monday the U.S. Food and Drug Administration has removed a clinical hold on the late-stage clinical trial for its experimental gene therapy for a ...

Frontline nivolumab plus AVD reduced risk of progression or death by 58% versus brentuximab vedotin plus AVD (PFS HR, 0.42) in advanced-stage classical Hodgkin lymphoma. CA209-8UT randomized 994 ...